1
|
Ito K, Nakagawa M, Hori K, Tashima L, Goto M, Yanagida S, Suzuki J, Kaya R, Kawabata A, Park J, Nasu H, Nishio S, Kondo E, Kaneda M, Tsubamoto H, Arakawa A, Nagasawa T, Yamada K. 834P A phase II study of gemcitabine, cisplatin, and bevacizumab for first recurrent and refractory ovarian clear-cell carcinoma (KCOG-G1601 trial). Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.973] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
2
|
Fujishiro A, Tsubamoto H, Higuchi Y, Kanematsu A, Shibahara H. Adolescent bladder endometriosis initially diagnosed as premenarchal disease: a case report and review of the literature. CLIN EXP OBSTET GYN 2018. [DOI: 10.12891/ceog3894.2018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022]
|
3
|
Itani Y, Arakawa A, Tsubamoto H, Ito K, Nishikawa R, Inoue K, Yamamoto S, Miyagi Y, Hori K, Furukawa N. Validation of the distress and impact thermometer and the changes of mood during the first 6 months of treatment in gynecological cancer patients: a Kansai Clinical Oncology Group (KCOG)-G1103 prospective study. Arch Gynecol Obstet 2016; 294:1273-1281. [PMID: 27488702 DOI: 10.1007/s00404-016-4166-y] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2015] [Accepted: 07/28/2016] [Indexed: 12/30/2022]
Abstract
PURPOSE To verify distress and impact thermometer (DIT) for screening emotional distress in gynecological cancer patients by Hospital Anxiety and Depression Scale total (HADS-T) as gold standard and to assess emotional changes by DIT and HADS-T. METHODS A prospective study was conducted in newly diagnosed gynecological cancer patients during the peri-treatment period after the cancer diagnosis followed by 6-month. We defined a HADS-T score of ≥11 as being indicative of emotional distress. RESULTS 117 patients were enrolled between May 1, 2011 and March 31, 2012, and 95 were eligible. The median age was 54 years (range 31-77). (1) From the baseline to 3-month, distress (DIT-D) ≥4 with Impact (DIT-I) ≥2 exhibited sensitivity, specificity, positive predictive value (PPV), and negative predictive values (NPV) of 0.776 [95 % confidential interval (CI) 0.688, 0.850], 0.889 (95 % CI 0.824, 0.954), 0.868 (95 % CI 0.792, 0.949), and 0.808 (95 % CI 0.731, 0.886), respectively. (2) At 6-month, DIT-D ≥2 with DIT-I ≥1 exhibited sensitivity, specificity, PPV and NPV of 0.893 (95 % CI 0.778, 1), 0.825 (95 % CI 0.707, 0.942), 0.781 (95 % CI 0.638, 0.928), and 0.917 (95 % CI 0.826, 1). (3) At 6-month, the HADS-T, DIT-D, and DIT-I scores in individual patients were significantly reduced by a mean of 4.57 (p < 0.0001), 2.34 (p < 0.0001), and 1.10 (p = 0.0031), respectively, compared with those scores of baseline (Student's paired t test), but still remained high. CONCLUSIONS (1) On acute phase within 3-month setting, DIT; DIT-D ≥4 with DIT-I ≥2, is a reliable cut-off to screen emotional distress among gynecological cancer patients. (2) The patients' moods had improved, but not completely recovered at 6-month after the diagnosis.
Collapse
Affiliation(s)
- Y Itani
- Department of Obstetrics and Gynecology, Nara Prefecture General Medical Center, Nara, Japan.
| | - A Arakawa
- Department of Obstetrics and Gynecology, Nagoya City University Graduate School of Medicine, Nagoya, Japan
| | - H Tsubamoto
- Department of Obstetrics and Gynecology, Hyogo College of Medicine, Nishinomiya, Japan
| | - K Ito
- Department of Obstetrics and Gynecology, Kansai Rosai Hospital, Amagasaki, Japan
| | - R Nishikawa
- Department of Obstetrics and Gynecology, Nagoya City University Graduate School of Medicine, Nagoya, Japan
| | - K Inoue
- Department of Obstetrics and Gynecology, Meiwa General Hospital, Amagasaki, Japan
| | - S Yamamoto
- Department of Obstetrics and Gynecology, Kansai Rosai Hospital, Amagasaki, Japan
| | - Y Miyagi
- Department of Gynecology Okayama, Ohfuku Clinic, Okayama, Japan
| | - K Hori
- Department of Obstetrics and Gynecology, Kansai Rosai Hospital, Amagasaki, Japan
| | - N Furukawa
- Department of Obstetrics and Gynecology, Nara Prefectural Seiwa Medical Center, Ikomagun-Sangocho, Japan
| |
Collapse
|
4
|
Tsubamoto H, Takeuchi S, Ito K, Miyagi Y, Toyoda S, Inoue K, Kanazawa R, Hosoda Y, Shibahara H. Feasibility and efficacy of intraperitoneal docetaxel administration as salvage chemotherapy for malignant gynaecological ascites. J OBSTET GYNAECOL 2014; 35:69-73. [PMID: 25020206 DOI: 10.3109/01443615.2014.935719] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Ovarian and endometrial cancers diagnosed at advanced stages are often associated with malignant ascites. This study aimed to determine the safety, feasibility and efficacy of intraperitoneal (IP) docetaxel (TXT) for the treatment of ascites. A phase I study, including nine patients, was undertaken to determine the maximum tolerable dose. Efficacy was retrospectively assessed in 18 patients treated with 40-70 mg/m(2) IP TXT between 2005 and 2012. In a phase I study, the dose was safely escalated to a maximum of 70 mg/m(2), at which level no patients had grade -3 haematological adverse events. In a retrospective study of 18 patients, seven had an Eastern Cooperative Oncology Group performance status of 3; 16 had prior paclitaxel administration and two, with doses of 40 and 70 mg/m(2), experienced a serological response and a decrease in paracentesis. Thus, palliative treatment of recurrent OC should be further studied with 40 mg/m(2) among more patients, and 70 mg/m(2) could be evaluated for first-line IP chemotherapy.
Collapse
Affiliation(s)
- H Tsubamoto
- Department of Obstetrics and Gynecology, Hyogo College of Medicine , Nishinomiya , Japan
| | | | | | | | | | | | | | | | | |
Collapse
|
5
|
Tsubamoto H, Wakimoto Y, Wada R, Takeyama R, Ito Y, Harada K. Detection of unruptured ovarian pregnancy subsequently successfully treated by conservative laparoscopic surgery: a case report and review of the literature. CLIN EXP OBSTET GYN 2013; 40:604-606. [PMID: 24597269] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
Early detection of ovarian pregnancy (OP) is essential for successful laparoscopic conservative surgery. However, early preoperative ultrasonography-based diagnosis is often difficult when fetal cardiac activity or the yolk sac is absent. The authors report a case of OP diagnosed at eight weeks gestational age in a natural pregnancy. The patient presented with amenorrhea and transient vaginal bleeding, and slight tenderness in the right ovary was noted during vaginal ultrasonography. Furthermore, ultrasonography showed a gestational sac (GS) without fetal cardiac activity or yolk sac, consistent with OP, and an adjacent compressible lutein cyst. The uterus, fallopian tubes, and left ovary were normal, and no cul-de-sac blood or ascites were found. Laparoscopy showed a two-cm mass partially covering the right ovary, which contained an unruptured GS. Subsequently, the mass was removed, and OP was histologically confirmed.
Collapse
Affiliation(s)
- H Tsubamoto
- Department of Obstetrics and Gynecology, Hyogo College of Medicine, Hyogo, Japan.
| | - Y Wakimoto
- Department of Obstetrics and Gynecology, Hyogo College of Medicine, Hyogo, Japan
| | - R Wada
- Department of Obstetrics and Gynecology, Hyogo College of Medicine, Hyogo, Japan
| | - R Takeyama
- Department of Obstetrics and Gynecology, Hyogo College of Medicine, Hyogo, Japan
| | - Y Ito
- Department of Obstetrics and Gynecology, Hyogo College of Medicine, Hyogo, Japan
| | - K Harada
- Department of Obstetrics and Gynecology, Hyogo College of Medicine, Hyogo, Japan
| |
Collapse
|
6
|
Inoue K, Tsubamoto H, Ito K, Hori K, Kanazawa R, Ito Y, Yamamoto S, Onishi K, Ando R, Komori S. Intraperitoneal and intrapleural administrations of triamcinolone acetonide for control of malignant ascites and pleural effusion. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e15505] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
7
|
Takekuma M, Hirashima Y, Ito K, Tsubamoto H, Tabata T, Arakawa A, Itani Y, Furukawa N, Murakoshi H, Takeuchi S. Phase II trial of paclitaxel and nedaplatin in patients with advanced/recurrent uterine cervical cancer: A Kansai Clinical Oncology Group study. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.5102] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
8
|
Tsubamoto H, Inoue K, Kawaguchi R, Ito K, Takeuchi S, Shiozaki T, Itani Y, Arakawa A, Tabata T, Toyoda S. Phase II trial of weekly irinotecan and carboplatin for relapsed ovarian cancer: A Kansai Clinical Oncology Group study. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.5089] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
9
|
Yanagi H, Kamikonya N, Yasui C, Aihara T, Ikuta S, Iida H, Tsubamoto H, Matsumoto S, Tomita N, Yamanaka N. Clinical results of preoperative chemoradiotherapy using short-term schedule (25 Gy) and long-term schedule (45-50.4 Gy) for lower rectal cancer. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e14035] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
10
|
Tsubamoto H, Wada R, Kanazawa R, Komori S, Maeda H, Hirota S, Adachi S. Neoadjuvant transarterial chemoembolization (TACE) using cisplatin with the combination of dose-dense intravenous administration of paclitaxel for the locally advanced cervical adenocarcinoma. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.e16518] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e16518 Background: Adenocarcinoma (including adenosquamous carcinoma) of the uterine cervix has a tendency to early lymph node metastasis and is resistant to radiation therapy, thus results in poor prognosis compared with squamous cell carcinoma. Neoadjuvant chemotherapy (NAC) followed by radical hysterectomy (RH) for bulky cervical adenocarcinoma seems to be an alternative therapy to primary radiation. Methods: P2 at the single institution. Eligible criteria were as follows: Histologically diagnosed cervical adeno or adenosquamous carcinoma with FIGO stage IB2-IVA, Age < or equal to 75, PS 0–2, given informed consent. The NAC regimen consisted of paclitaxel (60mg/m2, iv, D1, D8, D15) and cisplatin (70 mg/m2, trans-uterine arterial infusion followed by embolization using the gelform, D2) repeated every 3 weeks for 2–3 cycles, followed by RH. Primary endpoints were clinical and pathological responses, and secondary endpoints were toxicities, relapse free survival (RFS) and overall survival (OS). Results: Enrolled patients: 22 (1998–2006), Age: median 51 (33–75), FIGO stage: IB2 (9), IIA-IIB (8), IIIB (3), IVA (2), adeno/adenosquamous: 16/6. Toxicities during NAC (CTCAE ver.3) were as follows: G3/G4 neutropenia 18% (4/22), G3/G4 anemia 14% (3/22), G3/G4 thrombocytopenia 0%, G2/G3 sensory neuropathy 0 %, G3/G4 creatinine elevation 0%, G2 alopecia 100%. Clinical response rate (RR: CR+PR) of the patients with stage IB2-IIB was 100%. 16 of 17 received RH, and no residual malignant cells were found pathologically (pCR) in 3. RR of the patients with stage IIIb-IVa was 80%, three patients completed RH with either modified anterior or posterior exenteration, and pCR was found in one patient. The rate of radiation therapy following either NAC or surgery among enrolled patients were 18% (3/17) with stage IB2-IIB and 40% (2/5) with IIIB-IVA. 5 year RFS/OS were 69%/68% with stage IB2-IIb and 60%/60% with stage IIIb-IVa. All 15 alive patients had RH. One patient with stage IVa had urostomy, and other 14 patients have no trouble in urination function. Conclusions: TACE with cisplatin and dose dense paclitaxel in the neoadjuvant setting is feasible and effective for cervical adenocarcinoma. [Table: see text]
Collapse
Affiliation(s)
- H. Tsubamoto
- Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Kansai Clinical Oncology Group, Kansai, Japan
| | - R. Wada
- Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Kansai Clinical Oncology Group, Kansai, Japan
| | - R. Kanazawa
- Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Kansai Clinical Oncology Group, Kansai, Japan
| | - S. Komori
- Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Kansai Clinical Oncology Group, Kansai, Japan
| | - H. Maeda
- Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Kansai Clinical Oncology Group, Kansai, Japan
| | - S. Hirota
- Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Kansai Clinical Oncology Group, Kansai, Japan
| | - S. Adachi
- Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Kansai Clinical Oncology Group, Kansai, Japan
| |
Collapse
|
11
|
Tsubamoto H, Ito K, Itani Y, Ito K, Iijima T, Hosokawa K, Adachi S. Phase II study for the suboptimally debulked advanced ovarian cancer: Intravenous platinum followed by interval debulking surgery and intravenous paclitaxel + intraperitoneal cisplatin (KCOG9812 study). J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.5576] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
5576 Background: Intraperitoneral administration (IP) of cisplatin is recommended by National Cancer Institute for the patients with optimally debulked epitherial ovarian cancer (EOC). However, the advantage is not determined for the suboptimally debulked EOC after the initial surgery. We conducted a phase II study of cisplatin IP after the interval debulking surgery (IDS) following 3 cycles of intravenous platinum. Methods: The initial planned sample size was 30. Eligible patients had previously untreated, histologically confirmed EOC or primary peritoneal carcinoma (PPC) of FIGO stage IIIB-IV with suboptimal (> 1 cm) residual disease. Carboplatin AUC 4 iv d1 and cisplatin 50 mg/sqm iv d3 q21d for 3 cycles. After IDS, paclitaxel 175 mg/sqm iv d1 (or paclitaxel 60 mg/sqm iv d1,d8,d15) and cisplatin 75mg/m2 IP q21d for 4 cycles. Primary endpoint was progression-free survival (PFS) and secondary endpoints were overall survival (OS) and toxicity. Results: 33 patients were enrolled since 1998 till 2005. The median age was 55 (range 19–77). ECOG PS 0/1/2 = 33%/36%/31%; stage IIIB/IIIC/IV = 6%/64%/30%; 91% serous papillary histology. Optimal interval debulking surgery was possible in 85%: none (61%), < 1 cm (24%). Grade 3 or 4 (CTCAE ver.3) non-hematologic toxicity was seen in one patient of neurotoxicity. Grade 3 or 4 hematologic toxicities include: neutropenia (37%), infection (4%), thrombocytopenia (11%). 55% were completed the treatment schedule. The reasons for discontinuing were drug resistance (12%), subileus (4%), elevation of serum creatinine (12%), G3 neurotoxicity (4%), IP catheter block (12%) and infection (4%). Primary recurrent sites of total 20 patients before the second line chemotherapy or surgery were peritoneal cavity (30%), distant metastasis (45%), retroperitoneal lymph nodes (15%), and elevation of serum CA125 (10%). Median PFS was 24 months; median overall survival was 48 months; median follow-up was 36 months (range 15–100). Conclusions: This treatment including cisplatin IP after IDS for the patients with the initially suboptimally debulked EOC was feasible, and showed good prognosis with the small number of the intraperitoneal recurrence. [Table: see text]
Collapse
Affiliation(s)
- H. Tsubamoto
- Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Nara Prefectural Hospital, Nara, Japan; Kansai Rosai Hospital, Amagasaki, Japan; Nishinomiya Prefectural Hospital, Nishinomiya, Japan; Kyoto Prefectural Hospital, Kyoto, Japan; NPO Kansai Clinical Oncology Group, Kansai, Japan
| | - K. Ito
- Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Nara Prefectural Hospital, Nara, Japan; Kansai Rosai Hospital, Amagasaki, Japan; Nishinomiya Prefectural Hospital, Nishinomiya, Japan; Kyoto Prefectural Hospital, Kyoto, Japan; NPO Kansai Clinical Oncology Group, Kansai, Japan
| | - Y. Itani
- Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Nara Prefectural Hospital, Nara, Japan; Kansai Rosai Hospital, Amagasaki, Japan; Nishinomiya Prefectural Hospital, Nishinomiya, Japan; Kyoto Prefectural Hospital, Kyoto, Japan; NPO Kansai Clinical Oncology Group, Kansai, Japan
| | - K. Ito
- Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Nara Prefectural Hospital, Nara, Japan; Kansai Rosai Hospital, Amagasaki, Japan; Nishinomiya Prefectural Hospital, Nishinomiya, Japan; Kyoto Prefectural Hospital, Kyoto, Japan; NPO Kansai Clinical Oncology Group, Kansai, Japan
| | - T. Iijima
- Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Nara Prefectural Hospital, Nara, Japan; Kansai Rosai Hospital, Amagasaki, Japan; Nishinomiya Prefectural Hospital, Nishinomiya, Japan; Kyoto Prefectural Hospital, Kyoto, Japan; NPO Kansai Clinical Oncology Group, Kansai, Japan
| | - K. Hosokawa
- Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Nara Prefectural Hospital, Nara, Japan; Kansai Rosai Hospital, Amagasaki, Japan; Nishinomiya Prefectural Hospital, Nishinomiya, Japan; Kyoto Prefectural Hospital, Kyoto, Japan; NPO Kansai Clinical Oncology Group, Kansai, Japan
| | - S. Adachi
- Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Nara Prefectural Hospital, Nara, Japan; Kansai Rosai Hospital, Amagasaki, Japan; Nishinomiya Prefectural Hospital, Nishinomiya, Japan; Kyoto Prefectural Hospital, Kyoto, Japan; NPO Kansai Clinical Oncology Group, Kansai, Japan
| |
Collapse
|
12
|
Takeuchi S, Tsubamoto H, Adachi S, Ito K, Itani Y, Miyamoto T, Terai Y, Kigawa J, Sugiyama T. Intraperitoneal therapy for ovarian cancer: Impact on survival and recurrence—The result of multi-institutional studies. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.16068] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
16068 Background: For optimal debulked mullerian cancer (MC), the Intraperitoneal (IP) therapy has become the effective modality of chemotherapy to obtain better prognosis. We have reported KCOG9811study: IP CDDP + Paclitaxel (PTX) intravenous (IV) 2 cycles followed by 3 cycles of usual PTX-Carboplatin (abstr.1970, ASCO2002). And we have also reported the feasibility study and satisfactory response rate of the weekly IP-PTX with IV Carboplatin therapy (IP-PIVC, abstr. 5120, ASCO2005). Objectives: We have conducted two types of IP therapy for optimal debulked MC to improve the progression free survival (PFS) and overall survival (OS). Here are the prognosis and recurrent fashion after these IP therapies. Methods: Twenty patients (pts) with optimal debulked ovarian cancer were enrolled for KCOG9811, and eleven pts with optimal debulked MC newly/recurrent diagnosed disease were enrolled for IP-PIVC. The regimen of each therapy consisted of as follows: KCOG9811:50mg/ m2 of CDDP was administered via IP port at operation, after 2 weeks (wks) of operation, PTX was administered at a dose of 175mg/ m2IV for 3hrs on day 1, CDDP was administered at 75mg/ m2IP on day 2, every 3wks for 2 cycles, followed by PTX 175mg/ m2 IV and Carboplatin AUC5 IV on day1 every 3wks for 3 cycles. The IP-PIVC therapy consisted of IP-PTX, on days 1, 8, 15 at a dose of 45 mg/m2 (3pts) and 60 mg/m2(8pts). Carboplatin was administered monthly at a dose of AUC 5 on day 1 only. 2–6 cycles were performed. Results: The mean observation time was 72.6 months (m) and 32.6m for KCOG9811 and IP-PIVC, respectively. As for the median PFS was 1308+ days and 678+ days, and the median OS was 2180+ days and 978+ days, respectively. The five years survival rate showed 59.3% on KCOG9811, and the three years survival rate showed 75.8% on IP-PIVC. As for recurrent fashion, liver metastases and proximal lymphnodes metastases, and retroperitoneal metastases were detected. Few cases recurred Intraperitoneal lesion with small ascites Conclusions: There are some differences in the recurrent fashion of IP treatment from that of IV treatment. IP treatment prevented ascitic recurrence. Further improvement of chemotherapy is necessary for liver metastasis and proximal lymphnodes. [Table: see text]
Collapse
Affiliation(s)
- S. Takeuchi
- Nat'l Kobe Medical Center, Kobe, Japan; Hyogo College of Medicine, Nishinomiya, Japan; Eli Lilly and Company, Indianapolis, IN; Kansai Rosai Hospital, Amagasaki, Japan; Nara Hospital, Nara, Japan; Sanda Municipal Hospital, Sanda, Japan; Osaka Medical College, Takatsuki, Japan; Tottori University, Yonago, Japan; Iwate Medical University, Morioka, Japan
| | - H. Tsubamoto
- Nat'l Kobe Medical Center, Kobe, Japan; Hyogo College of Medicine, Nishinomiya, Japan; Eli Lilly and Company, Indianapolis, IN; Kansai Rosai Hospital, Amagasaki, Japan; Nara Hospital, Nara, Japan; Sanda Municipal Hospital, Sanda, Japan; Osaka Medical College, Takatsuki, Japan; Tottori University, Yonago, Japan; Iwate Medical University, Morioka, Japan
| | - S. Adachi
- Nat'l Kobe Medical Center, Kobe, Japan; Hyogo College of Medicine, Nishinomiya, Japan; Eli Lilly and Company, Indianapolis, IN; Kansai Rosai Hospital, Amagasaki, Japan; Nara Hospital, Nara, Japan; Sanda Municipal Hospital, Sanda, Japan; Osaka Medical College, Takatsuki, Japan; Tottori University, Yonago, Japan; Iwate Medical University, Morioka, Japan
| | - K. Ito
- Nat'l Kobe Medical Center, Kobe, Japan; Hyogo College of Medicine, Nishinomiya, Japan; Eli Lilly and Company, Indianapolis, IN; Kansai Rosai Hospital, Amagasaki, Japan; Nara Hospital, Nara, Japan; Sanda Municipal Hospital, Sanda, Japan; Osaka Medical College, Takatsuki, Japan; Tottori University, Yonago, Japan; Iwate Medical University, Morioka, Japan
| | - Y. Itani
- Nat'l Kobe Medical Center, Kobe, Japan; Hyogo College of Medicine, Nishinomiya, Japan; Eli Lilly and Company, Indianapolis, IN; Kansai Rosai Hospital, Amagasaki, Japan; Nara Hospital, Nara, Japan; Sanda Municipal Hospital, Sanda, Japan; Osaka Medical College, Takatsuki, Japan; Tottori University, Yonago, Japan; Iwate Medical University, Morioka, Japan
| | - T. Miyamoto
- Nat'l Kobe Medical Center, Kobe, Japan; Hyogo College of Medicine, Nishinomiya, Japan; Eli Lilly and Company, Indianapolis, IN; Kansai Rosai Hospital, Amagasaki, Japan; Nara Hospital, Nara, Japan; Sanda Municipal Hospital, Sanda, Japan; Osaka Medical College, Takatsuki, Japan; Tottori University, Yonago, Japan; Iwate Medical University, Morioka, Japan
| | - Y. Terai
- Nat'l Kobe Medical Center, Kobe, Japan; Hyogo College of Medicine, Nishinomiya, Japan; Eli Lilly and Company, Indianapolis, IN; Kansai Rosai Hospital, Amagasaki, Japan; Nara Hospital, Nara, Japan; Sanda Municipal Hospital, Sanda, Japan; Osaka Medical College, Takatsuki, Japan; Tottori University, Yonago, Japan; Iwate Medical University, Morioka, Japan
| | - J. Kigawa
- Nat'l Kobe Medical Center, Kobe, Japan; Hyogo College of Medicine, Nishinomiya, Japan; Eli Lilly and Company, Indianapolis, IN; Kansai Rosai Hospital, Amagasaki, Japan; Nara Hospital, Nara, Japan; Sanda Municipal Hospital, Sanda, Japan; Osaka Medical College, Takatsuki, Japan; Tottori University, Yonago, Japan; Iwate Medical University, Morioka, Japan
| | - T. Sugiyama
- Nat'l Kobe Medical Center, Kobe, Japan; Hyogo College of Medicine, Nishinomiya, Japan; Eli Lilly and Company, Indianapolis, IN; Kansai Rosai Hospital, Amagasaki, Japan; Nara Hospital, Nara, Japan; Sanda Municipal Hospital, Sanda, Japan; Osaka Medical College, Takatsuki, Japan; Tottori University, Yonago, Japan; Iwate Medical University, Morioka, Japan
| |
Collapse
|
13
|
Ito K, Adachi S, Itani Y, Nobunaga T, Shintani M, Tsubamoto H, Hosokawa K, Fujita H, Nakata Y, Yamazaki N. Phase II trial of weekly paclitaxel and carboplatin (wTJ) for endometrial cancer (EC): Results of a Kansai Clinical Oncology Group trial (KCOG0015) in Japan. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.5085] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- K. Ito
- Kansai Rosai Hospital, Amagasaki, Japan; Hyogo madical college, Nishinomiya, Japan; Nara Prefectural Nara Hospital, Nara, Japan; Hyogo Prefectural Nishinomiya Hospital, Nishinomiya, Japan; Nara Prefectural Mimuro Hospital, Ikoma-gun, Japan; Hyogo Medical College, Nishinomiya, Japan; Kyoto Prefectural University of Medicine, Kyoto, Japan; Kyoto Second Red Cross Hospital, Kyoto, Japan; Kyoto First Red Cross Hospital, Kyoto, Japan; Minamiosaka Hospital, Osaka, Japan
| | - S. Adachi
- Kansai Rosai Hospital, Amagasaki, Japan; Hyogo madical college, Nishinomiya, Japan; Nara Prefectural Nara Hospital, Nara, Japan; Hyogo Prefectural Nishinomiya Hospital, Nishinomiya, Japan; Nara Prefectural Mimuro Hospital, Ikoma-gun, Japan; Hyogo Medical College, Nishinomiya, Japan; Kyoto Prefectural University of Medicine, Kyoto, Japan; Kyoto Second Red Cross Hospital, Kyoto, Japan; Kyoto First Red Cross Hospital, Kyoto, Japan; Minamiosaka Hospital, Osaka, Japan
| | - Y. Itani
- Kansai Rosai Hospital, Amagasaki, Japan; Hyogo madical college, Nishinomiya, Japan; Nara Prefectural Nara Hospital, Nara, Japan; Hyogo Prefectural Nishinomiya Hospital, Nishinomiya, Japan; Nara Prefectural Mimuro Hospital, Ikoma-gun, Japan; Hyogo Medical College, Nishinomiya, Japan; Kyoto Prefectural University of Medicine, Kyoto, Japan; Kyoto Second Red Cross Hospital, Kyoto, Japan; Kyoto First Red Cross Hospital, Kyoto, Japan; Minamiosaka Hospital, Osaka, Japan
| | - T. Nobunaga
- Kansai Rosai Hospital, Amagasaki, Japan; Hyogo madical college, Nishinomiya, Japan; Nara Prefectural Nara Hospital, Nara, Japan; Hyogo Prefectural Nishinomiya Hospital, Nishinomiya, Japan; Nara Prefectural Mimuro Hospital, Ikoma-gun, Japan; Hyogo Medical College, Nishinomiya, Japan; Kyoto Prefectural University of Medicine, Kyoto, Japan; Kyoto Second Red Cross Hospital, Kyoto, Japan; Kyoto First Red Cross Hospital, Kyoto, Japan; Minamiosaka Hospital, Osaka, Japan
| | - M. Shintani
- Kansai Rosai Hospital, Amagasaki, Japan; Hyogo madical college, Nishinomiya, Japan; Nara Prefectural Nara Hospital, Nara, Japan; Hyogo Prefectural Nishinomiya Hospital, Nishinomiya, Japan; Nara Prefectural Mimuro Hospital, Ikoma-gun, Japan; Hyogo Medical College, Nishinomiya, Japan; Kyoto Prefectural University of Medicine, Kyoto, Japan; Kyoto Second Red Cross Hospital, Kyoto, Japan; Kyoto First Red Cross Hospital, Kyoto, Japan; Minamiosaka Hospital, Osaka, Japan
| | - H. Tsubamoto
- Kansai Rosai Hospital, Amagasaki, Japan; Hyogo madical college, Nishinomiya, Japan; Nara Prefectural Nara Hospital, Nara, Japan; Hyogo Prefectural Nishinomiya Hospital, Nishinomiya, Japan; Nara Prefectural Mimuro Hospital, Ikoma-gun, Japan; Hyogo Medical College, Nishinomiya, Japan; Kyoto Prefectural University of Medicine, Kyoto, Japan; Kyoto Second Red Cross Hospital, Kyoto, Japan; Kyoto First Red Cross Hospital, Kyoto, Japan; Minamiosaka Hospital, Osaka, Japan
| | - K. Hosokawa
- Kansai Rosai Hospital, Amagasaki, Japan; Hyogo madical college, Nishinomiya, Japan; Nara Prefectural Nara Hospital, Nara, Japan; Hyogo Prefectural Nishinomiya Hospital, Nishinomiya, Japan; Nara Prefectural Mimuro Hospital, Ikoma-gun, Japan; Hyogo Medical College, Nishinomiya, Japan; Kyoto Prefectural University of Medicine, Kyoto, Japan; Kyoto Second Red Cross Hospital, Kyoto, Japan; Kyoto First Red Cross Hospital, Kyoto, Japan; Minamiosaka Hospital, Osaka, Japan
| | - H. Fujita
- Kansai Rosai Hospital, Amagasaki, Japan; Hyogo madical college, Nishinomiya, Japan; Nara Prefectural Nara Hospital, Nara, Japan; Hyogo Prefectural Nishinomiya Hospital, Nishinomiya, Japan; Nara Prefectural Mimuro Hospital, Ikoma-gun, Japan; Hyogo Medical College, Nishinomiya, Japan; Kyoto Prefectural University of Medicine, Kyoto, Japan; Kyoto Second Red Cross Hospital, Kyoto, Japan; Kyoto First Red Cross Hospital, Kyoto, Japan; Minamiosaka Hospital, Osaka, Japan
| | - Y. Nakata
- Kansai Rosai Hospital, Amagasaki, Japan; Hyogo madical college, Nishinomiya, Japan; Nara Prefectural Nara Hospital, Nara, Japan; Hyogo Prefectural Nishinomiya Hospital, Nishinomiya, Japan; Nara Prefectural Mimuro Hospital, Ikoma-gun, Japan; Hyogo Medical College, Nishinomiya, Japan; Kyoto Prefectural University of Medicine, Kyoto, Japan; Kyoto Second Red Cross Hospital, Kyoto, Japan; Kyoto First Red Cross Hospital, Kyoto, Japan; Minamiosaka Hospital, Osaka, Japan
| | - N. Yamazaki
- Kansai Rosai Hospital, Amagasaki, Japan; Hyogo madical college, Nishinomiya, Japan; Nara Prefectural Nara Hospital, Nara, Japan; Hyogo Prefectural Nishinomiya Hospital, Nishinomiya, Japan; Nara Prefectural Mimuro Hospital, Ikoma-gun, Japan; Hyogo Medical College, Nishinomiya, Japan; Kyoto Prefectural University of Medicine, Kyoto, Japan; Kyoto Second Red Cross Hospital, Kyoto, Japan; Kyoto First Red Cross Hospital, Kyoto, Japan; Minamiosaka Hospital, Osaka, Japan
| |
Collapse
|
14
|
Itani Y, Adachi S, Ito K, Takeuchi S, Akiyama M, Hosokawa K, Tabata T, Tsubamoto H, Fujita H, Nakamura H. Phase I/II study of a docetaxel (DOC) and gemcitabine (GEM) combination for early recurrent (≤12 months)(ER) or refractory (R) epithelial ovarian cancer (EOC): Kansai Clinical Oncology Group, Japan. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.5046] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Y. Itani
- Nara Prefectural Nara Hospital, Nara, Japan; Hyogo Medical College, Nishinomiya, Japan; Kansai Rosai Hospital, Amagasaki, Japan; Kobe National Hospital, Kobe, Japan; Shiga Medical College, Otsu, Japan; Kyoto Prefectural University of Medicine, Kyoto, Japan; Mie University, Tsu, Japan; Kyoto Second Red Cross Hospital, Kyoto, Japan; Osaka City General Hospital, Osaka, Japan
| | - S. Adachi
- Nara Prefectural Nara Hospital, Nara, Japan; Hyogo Medical College, Nishinomiya, Japan; Kansai Rosai Hospital, Amagasaki, Japan; Kobe National Hospital, Kobe, Japan; Shiga Medical College, Otsu, Japan; Kyoto Prefectural University of Medicine, Kyoto, Japan; Mie University, Tsu, Japan; Kyoto Second Red Cross Hospital, Kyoto, Japan; Osaka City General Hospital, Osaka, Japan
| | - K. Ito
- Nara Prefectural Nara Hospital, Nara, Japan; Hyogo Medical College, Nishinomiya, Japan; Kansai Rosai Hospital, Amagasaki, Japan; Kobe National Hospital, Kobe, Japan; Shiga Medical College, Otsu, Japan; Kyoto Prefectural University of Medicine, Kyoto, Japan; Mie University, Tsu, Japan; Kyoto Second Red Cross Hospital, Kyoto, Japan; Osaka City General Hospital, Osaka, Japan
| | - S. Takeuchi
- Nara Prefectural Nara Hospital, Nara, Japan; Hyogo Medical College, Nishinomiya, Japan; Kansai Rosai Hospital, Amagasaki, Japan; Kobe National Hospital, Kobe, Japan; Shiga Medical College, Otsu, Japan; Kyoto Prefectural University of Medicine, Kyoto, Japan; Mie University, Tsu, Japan; Kyoto Second Red Cross Hospital, Kyoto, Japan; Osaka City General Hospital, Osaka, Japan
| | - M. Akiyama
- Nara Prefectural Nara Hospital, Nara, Japan; Hyogo Medical College, Nishinomiya, Japan; Kansai Rosai Hospital, Amagasaki, Japan; Kobe National Hospital, Kobe, Japan; Shiga Medical College, Otsu, Japan; Kyoto Prefectural University of Medicine, Kyoto, Japan; Mie University, Tsu, Japan; Kyoto Second Red Cross Hospital, Kyoto, Japan; Osaka City General Hospital, Osaka, Japan
| | - K. Hosokawa
- Nara Prefectural Nara Hospital, Nara, Japan; Hyogo Medical College, Nishinomiya, Japan; Kansai Rosai Hospital, Amagasaki, Japan; Kobe National Hospital, Kobe, Japan; Shiga Medical College, Otsu, Japan; Kyoto Prefectural University of Medicine, Kyoto, Japan; Mie University, Tsu, Japan; Kyoto Second Red Cross Hospital, Kyoto, Japan; Osaka City General Hospital, Osaka, Japan
| | - T. Tabata
- Nara Prefectural Nara Hospital, Nara, Japan; Hyogo Medical College, Nishinomiya, Japan; Kansai Rosai Hospital, Amagasaki, Japan; Kobe National Hospital, Kobe, Japan; Shiga Medical College, Otsu, Japan; Kyoto Prefectural University of Medicine, Kyoto, Japan; Mie University, Tsu, Japan; Kyoto Second Red Cross Hospital, Kyoto, Japan; Osaka City General Hospital, Osaka, Japan
| | - H. Tsubamoto
- Nara Prefectural Nara Hospital, Nara, Japan; Hyogo Medical College, Nishinomiya, Japan; Kansai Rosai Hospital, Amagasaki, Japan; Kobe National Hospital, Kobe, Japan; Shiga Medical College, Otsu, Japan; Kyoto Prefectural University of Medicine, Kyoto, Japan; Mie University, Tsu, Japan; Kyoto Second Red Cross Hospital, Kyoto, Japan; Osaka City General Hospital, Osaka, Japan
| | - H. Fujita
- Nara Prefectural Nara Hospital, Nara, Japan; Hyogo Medical College, Nishinomiya, Japan; Kansai Rosai Hospital, Amagasaki, Japan; Kobe National Hospital, Kobe, Japan; Shiga Medical College, Otsu, Japan; Kyoto Prefectural University of Medicine, Kyoto, Japan; Mie University, Tsu, Japan; Kyoto Second Red Cross Hospital, Kyoto, Japan; Osaka City General Hospital, Osaka, Japan
| | - H. Nakamura
- Nara Prefectural Nara Hospital, Nara, Japan; Hyogo Medical College, Nishinomiya, Japan; Kansai Rosai Hospital, Amagasaki, Japan; Kobe National Hospital, Kobe, Japan; Shiga Medical College, Otsu, Japan; Kyoto Prefectural University of Medicine, Kyoto, Japan; Mie University, Tsu, Japan; Kyoto Second Red Cross Hospital, Kyoto, Japan; Osaka City General Hospital, Osaka, Japan
| |
Collapse
|
15
|
Hasegawa A, Sawai H, Tsubamoto H, Hori M, Isojima S, Koyama K. Possible presence of O-linked carbohydrate in the human male reproductive tract CD52. J Reprod Immunol 2004; 62:91-100. [PMID: 15288185 DOI: 10.1016/j.jri.2003.12.004] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Revised: 12/05/2003] [Accepted: 12/08/2003] [Indexed: 11/24/2022]
Abstract
Male reproductive tract CD52 (mrtCD52) is an antigen recognized by a complement-dependent sperm-immobilizing monoclonal antibody (SI-Abs) derived in an infertile patient. The molecule has been shown to contain a unique N-linked carbohydrate that does not cross-react with other tissues. In this study, we have investigated whether O-linked carbohydrate as well as N-linked carbohydrate is present in mrtCD52 using specific lectins and anti-CD52 core peptide antiserum. The lectin PNA, which recognizes O-linked carbohydrate [Galbeta1-3GalNAc], reacted with mrtCD52 and showed a similar polymorphic reaction pattern to that of the anti-peptide antiserum in western blotting analysis on two-dimensional SDS-PAGE. The PNA-reactive spots disappeared after removal of O-linked carbohydrate, but not after removal of N-linked carbohydrate. These results suggest that O-linked carbohydrate is present in mrtCD52. The moiety may possibly contribute to a specific antigenic epitope of mrtCD52.
Collapse
Affiliation(s)
- A Hasegawa
- Laboratory of Developmental Biology and Reproduction, Institute for Advanced Medical Sciences, Hyogo College of Medicine, Nishinomiya, Japan
| | | | | | | | | | | |
Collapse
|
16
|
Hasegawa A, Fu Y, Tsubamoto H, Tsuji Y, Sawai H, Komori S, Koyama K. Epitope analysis for human sperm-immobilizing monoclonal antibodies, MAb H6-3C4, 1G12 and campath-1. Mol Hum Reprod 2003; 9:337-43. [PMID: 12771234 DOI: 10.1093/molehr/gag045] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Human monoclonal antibody, MAb H6-3C4, possesses strong sperm immobilizing activity. MAb H6-3C4 has been suggested by several research groups to react with a carbohydrate moiety of male reproductive tract CD52 (mrtCD52). In the present study, we analysed the epitope on mrtCD52 for MAb H6-3C4 and found that it was polymorphic in Western blot analysis and disappeared after enzymatic removal of the N-linked carbohydrate moiety. Two other monoclonal antibodies (1G12, campath-1) with sperm-immobilizing activity recognized mrtCD52 in a polymorphic manner similar to MAb H6-3C4. Further analysis showed that 1G12 recognized a structure formed by the peptide and/or a glycosylphosphatidylinositol (GPI) anchor portion as does campath-1. Results of a lectin binding assay suggested the presence of O-linked carbohydrates on mrtCD52. Our results also indicated that the peptide portion of CD52 could serve as an epitope for sperm-immobilizing antibodies. It was concluded that the epitope of MAb H6-3C4 is similar to, but distinct from, those of 1G12 and campath-1, and that mrtCD52 contains different antigenic epitopes.
Collapse
Affiliation(s)
- A Hasegawa
- Laboratory of Developmental Biology and Reproduction, Institute for Advanced Medical Sciences, Nishinomiya, Japan
| | | | | | | | | | | | | |
Collapse
|
17
|
Adachi S, Ogasawara T, Tsubamoto H, Oku H, Hori Y, Tsuji Y, Takemura T, Koyama K. Intravenous nedaplatin and intraarterial cisplatin with transcatheter arterial embolization for patients with locally advanced uterine cervical cancer. Int J Clin Pharmacol Res 2002; 21:105-10. [PMID: 12067139] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/25/2023]
Abstract
Nedaplatin is a platinum analog that has less renal toxicity and higher efficacy for uterine cervical cancer than cisplatin. Intraarterial cisplatin has been shown to be more effective than intravenous cisplatin in the treatment of cervical cancer. To improve the prognosis of cervical cancer, we studied combination chemotherapy of intravenous nedaplatin and intraarticular cisplatin with transcatheter arterial embolization (TAE). The criteria for selecting patients for this study were as follows: age 16-75 years, stage Ib2-IV according to the classification of the International Federation of Gynecology and Obstetrics (FIGO), performance status between 0 and 2, a creatinine clearance of >40 ml/min, adequate bone marrow and adequate renal and hepatic function. Thirty-two patients, aged 29-72 years (median: 55) were treated. FIGO stage was Ib2 in seven patients, IIa in seven patients, IIb in four, IIIa in one, IIIb in seven and IVa in six. Twenty-four patients had squamous cell carcinoma, three had adenocarcinoma and five had adenosquamous carcinoma. Written informed consent was obtained from all patients. Nedaplatin (30-70 mg/m2) was administered intravenously on day 1 and cisplatin (70 mg/m2) was administered intraarticularly via both uterine arteries on day 3 using the Seldinger method. TAE was then performed. This course of treatment was repeated every 3 weeks for 2-3 cycles. Response to the therapy was defined by magnetic resonance imaging. Partial response was found in 59% patients (19/32) and complete response in 34% (11/32), with an overall response rate of 94% (30/32). Myelosuppression was manageable. No grade 2 neurotoxicity was observed. The median follow-up was 32 months (6-53 months), with 84% of patients showing an overall survival of 1 year and 77% showing an overall survival of 2 years. These results show that this combination chemotherapy effected a high response rate. However, its influence on long-term survival remains to be determined.
Collapse
Affiliation(s)
- S Adachi
- Department of Obstetrics and Gynecology, Hyogo College of Medicine, Japan.
| | | | | | | | | | | | | | | |
Collapse
|
18
|
Hasegawa A, Tsubamoto H, Hamada Y, Koyama K. Blocking effect of antisera to recombinant zona pellucida proteins (r-ZPA) on in vitro fertilization. Am J Reprod Immunol 2000; 44:59-64. [PMID: 10976814 DOI: 10.1111/j.8755-8920.2000.440109.x] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
Abstract
PROBLEM The zona pellucida is a good target antigen for contraceptive vaccines due to its strong immunogenicity and high tissue specificity. However, this contraceptive effect is inevitably associated with ovarian failure. Therefore, it is necessary to define an epitope of the zona antigen to which the antibody produced inhibits fertilization without any undesirable side effects. METHOD OF STUDY The DNA fragment coding for the NH2-terminal region of porcine zona pellucida proteins (ZPA) (1-198 amino acids) and human ZPA (1-206 amino acids) was prepared to produce recombinant porcine ZPA (r-ZPA), r-pZPA1-198 and r-hZPA1-206. Using Freund's complete adjuvant. antisera against these proteins were raised in rabbits. RESULTS The resultant antisera to r-pZPA1-198 and r-hZPA1-206 were cross-reacted with each other on enzyme-linked immunosorbent assay and immunofluorescent staining. The antiserum to r-pZPA1-198 inhibited in vitro fertilization in pigs, but not human sperm binding to the zona pellucida, while the antiserum to r-hZPA1-206 inhibited the human sperm-binding assay. CONCLUSIONS Antiserum to r-ZPA inhibited fertilization in the animal species possessing a homologous amino-acid sequence as an immunogen. The recombinant protein, r-hZPA1-206 seems to be a feasible candidate for the development of contraceptive vaccines for humans.
Collapse
Affiliation(s)
- A Hasegawa
- Laboratory of Developmental Biology and Reproduction, Institute of Advanced Medical Science, Hyogo College of Medicine, Nishinomiya, Japan
| | | | | | | |
Collapse
|
19
|
Abstract
A multigravida patient with polyarthralgia and eruptions on the head and fingers was seen at 6 weeks' gestation. No histological examination was performed before the current pregnancy. She developed severe early onset preeclampsia associated with swelling of the knees and increased cutaneous nodules, biopsies of which revealed multicentric reticulohistiocytosis. At 28 weeks' gestation an elective cesarean section was performed and a 580-g male infant was delivered.
Collapse
Affiliation(s)
- H Tsubamoto
- Dept. of Obstetrics and Gynecology, Self Defence Force Hanshin Hospital, Kawanishi, Hyogo, Japan.
| | | | | |
Collapse
|
20
|
Tsubamoto H, Hasegawa A, Nakata Y, Naito S, Yamasaki N, Koyama K. Expression of recombinant human zona pellucida protein 2 and its binding capacity to spermatozoa. Biol Reprod 1999; 61:1649-54. [PMID: 10570015 DOI: 10.1095/biolreprod61.6.1649] [Citation(s) in RCA: 52] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
Abstract
The human zona pellucida (ZP) is composed of three major glycoproteins: ZP1, ZP2, and ZP3. The aim of this study was to clarify the role of ZP2 by focusing on the polypeptide structure. We produced in Escherichia coli a recombinant human ZP2 protein (rec-hZP2) corresponding to amino acid sequence 1-206 of the mature protein. The final yield of rec-hZP2 protein was 80 microg/ml Luria Broth medium. After 2-h incubation of human spermatozoa with rec-hZP2 in vitro, an immunofluorescent study indicated that rec-hZP2 bound only to acrosome-reacted spermatozoa. The binding site migrated from the acrosome to the midpiece of the spermatozoa. Rabbit and mouse antisera produced against rec-hZP2 stained native human ZP in the immunofluorescent study, and significantly blocked human sperm binding and penetration into human ZP as compared to control values. The N-terminal polypeptide portion of human ZP2 was shown to contain a binding site for acrosome-reacted spermatozoa and to play an important role in secondary sperm binding and penetration into the ZP.
Collapse
Affiliation(s)
- H Tsubamoto
- Department of Obstetrics and Gynecology, Institute of Advanced Medical Sciences, Hyogo College of Medicine, Nishinomiya, 663-8501, Japan
| | | | | | | | | | | |
Collapse
|
21
|
Abstract
Porcine zona pellucida glycoprotein (pZP1) is a good candidate for a contraceptive vaccine. For the purpose of producing glycosylated pZP1, several types of recombinant pZP1 proteins were produced in mammalian cell lines. In the first experiment, a minigene encoding pZP1 (681 amino acids) was designed for insertion into an expression vector and then transfected to three cell lines (293T, CHO-K1, and LLC-PK1). The resulting recombinant proteins were highly glycosylated and were localized in the cytoplasm. To produce a secretory type of recombinant pZP1, in the second experiment, a cDNA coding for pZP1 excluding a putative transmembrane region and a smaller cDNA coding for 1-198 amino acid residues of pZP1 were designed to produce fusion proteins with the human IgG1 heavy chain. The resultant recombinant proteins were secreted into the supernatant from both transfected cell cultures. Recombinant secretory proteins are useful because of their simple affinity purification.
Collapse
Affiliation(s)
- H Tsubamoto
- Department of Obstetrics and Gynecology, Hyogo College of Medicine, Nishinomiya, 663-8501, Japan
| | | | | | | |
Collapse
|
22
|
Taya T, Yamasaki N, Tsubamoto H, Hasegawa A, Koyama K. Cloning of a cDNA coding for porcine zona pellucida glycoprotein ZP1 and its genomic organization. Biochem Biophys Res Commun 1995; 207:790-9. [PMID: 7864874 DOI: 10.1006/bbrc.1995.1256] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
The zona pellucida composed of three or four glycoproteins plays important roles in fertilization. Our previous study showed that porcine ZP1, one of the major glycoproteins of porcine zona pellucida, was divided into two components (porcine ZP4 and ZP2), and suggested it was a homologue of mouse ZP2. In this paper we report the cloning of a cDNA for porcine ZP1 and its genomic organization. The deduced amino acid sequence of porcine ZP1 shared a 54% and 63% identity with those of mouse and human ZP2, respectively. Genomic organization of porcine ZP1 was also similar to that of mouse ZP2. The transcript of porcine ZP1 gene was detected only in growing oocytes.
Collapse
Affiliation(s)
- T Taya
- Department of Obstetrics and Gynecology, Hyogo College of Medicine, Nishinomiya, Japan
| | | | | | | | | |
Collapse
|